A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

• Protocol code: VX18-445-110
• EudraCT code: 2019-000833-37
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  Álvarez Fernandez, Antonio
• Phase: Fase III
• Status: Recruiting volunteers